Loss of SH3 domain-binding protein 2 function suppresses bone destruction in tumor necrosis factor-driven and collagen-induced arthritis in mice

Arthritis and Rheumatology

Volumn 67, Issue 3, 2015, Pages 656-667

  Mukai, Tomoyuki ^a   Gallant, Richard ^a   Ishida, Shu ^a   Kittaka, Mizuho ^a   Yoshitaka, Teruhito ^a   Fox, David A ^c   Morita, Yoshitaka ^d   Nishida, Keiichiro ^e   Rottapel, Robert ^b   Ueki, Yasuyoshi ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF MICHIGAN   (United States)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; COLLAGEN TYPE 2; COLONY STIMULATING FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN SH3; SH3 DOMAIN BINDING PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTOANTIBODY; MESSENGER RNA; SH3BP2 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTHRITIS; ARTICLE; BONE DESTRUCTION; BONE EROSION; BONE MARROW DERIVED MACROPHAGE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; JOINT SWELLING; LYMPH NODE CELL; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; TALUS; TIBIA; WILD TYPE; ANIMAL; ARTHRITIS, EXPERIMENTAL; BLOOD; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; OSTEOCLAST; PATHOLOGY; PHYSIOLOGY; PREVENTION AND CONTROL; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; BLOTTING, WESTERN; BONE RESORPTION; COLLAGEN TYPE II; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; X-RAY MICROTOMOGRAPHY;

EID: 84923591349     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38975     Document Type: Article

References (50)

1. Pettit AR, Ji H, von Steechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159: 1689-99.
2. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002; 110: 1419-27.
3. McInnes IB, Schett G,. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
4. Redlich K, Smolen JS,. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012; 11: 234-50.
5. Schett G, Gravallese E,. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012; 8: 656-64.
6. Takayanagi H,. New developments in osteoimmunology. Nat Rev Rheumatol 2012; 8: 684-9.
7. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL,. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-8.
8. O'Gradaigh D, Ireland D, Bord S, Compston JE,. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor α, interleukin 1, and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004; 63: 354-9.
9. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ,. TNFα potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002; 143: 1108-18.
10. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-86.
11. Geusens P, Lems WF,. Osteoimmunology and osteoporosis. Arthritis Res Ther 2011; 13: 242.
12. Gough AK, Lilley J, Eyre S, Holder RL, Emery P,. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344: 23-7.
13. Vander Cruyssen B, Peene I, Cantaert T, Hoffman IE, De Rycke L, Veys EM, et al. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev 2005; 4: 468-74.
14. Deckert M, Tartare-Deckert S, Hernandez J, Rottapel R, Altman A,. Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. Immunity 1998; 9: 595-605.
15. Jevremovic D, Billadeau DD, Schoon RA, Dick CJ, Leibson PJ,. Regulation of NK cell-mediated cytotoxicity by the adaptor protein 3BP2. J Immunol 2001; 166: 7219-28.
16. Levaot N, Simoncic PD, Dimitriou ID, Scotter A, La Rose J, Ng AH, et al. 3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions. J Clin Invest 2011; 121: 3244-57.
17. GuezGuez A, Prod'homme V, Mouska X, Baudot A, Blin-Wakkach C, Rottapel R, et al. 3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells. J Biol Chem 2010; 285: 20952-63.
18. Chen G, Dimitriou ID, La Rose J, Ilangumaran S, Yeh WC, Doody G, et al. The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response. Mol Cell Biol 2007; 27: 3109-22.
19. De la Fuente MA, Kumar L, Lu B, Geha RS,. 3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation. Mol Cell Biol 2006; 26: 5214-25.
20. Sada K, Miah SM, Maeno K, Kyo S, Qu X, Yamamura H,. Regulation of FcεRI-mediated degranulation by an adaptor protein 3BP2 in rat basophilic leukemia RBL-2H3 cells. Blood 2002; 100: 2138-44.
21. Ueki Y, Lin CY, Senoo M, Ebihara T, Agata N, Onji M, et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 2007; 128: 71-83.
22. Tiziani V, Reichenberger E, Buzzo CL, Niazi S, Fukai N, Stiller M, et al. The gene for cherubism maps to chromosome 4p16. Am J Hum Genet 1999; 65: 158-66.
23. Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, Garfinkle J, et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001; 28: 125-6.
24. Papadaki ME, Lietman SA, Levine MA, Olsen BR, Kaban LB, Reichenberger EJ,. Cherubism: best clinical practice. Orphanet J Rare Dis 2012; 7 Suppl 1: S6.
25. Southgate J, Sarma U, Townend JV, Barron J, Flanagan AM,. Study of the cell biology and biochemistry of cherubism. J Clin Pathol 1998; 51: 831-7.
26. Kawamoto T, Fan C, Gaivin RJ, Levine MA, Lietman SA,. Decreased SH3BP2 inhibits osteoclast differentiation and function. J Orthop Res 2011; 29: 1521-7.
27. Hayward MD, Jones BK, Saparov A, Hain HS, Trillat AC, Bunzel MM, et al. An extensive phenotypic characterization of the hTNFα transgenic mice. BMC Physiol 2007; 7: 13.
28. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31.
29. Seki N, Sudo Y, Yoshioka T, Sugihara S, Fujitsu T, Sakuma S, et al. Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J Immunol 1988; 140: 1477-84.
30. Cho YG, Cho ML, Min SY, Kim HY,. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 2007; 7: 65-70.
31. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013; 28: 2-17.
32. Proulx ST, Kwok E, You Z, Papuga MO, Beck CA, Shealy DJ, et al. Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum 2007; 56: 4024-37.
33. Mukai T, Ishida S, Ishikawa R, Yoshitaka T, Kittaka M, Gallant R, et al. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss. J Bone Miner Res 2014; 29: 618-35.
34. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R,. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010; 25: 1468-86.
35. Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 1275-84.
36. Brand DD, Latham KA, Rosloniec EF,. Collagen-induced arthritis. Nat Protoc 2007; 2: 1269-75.
37. Inglis JJ, Simelyte E, McCann FE, Criado G, Williams RO,. Protocol for the induction of arthritis in C57BL/6 mice. Nat Protoc 2008; 3: 612-8.
38. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008; 118: 3775-89.
39. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901.
40. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med 2009; 15: 1066-71.
41. Yao Z, Xing L, Boyce BF,. NF-κB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest 2009; 119: 3024-34.
42. Zhao B, Grimes SN, Li S, Hu X, Ivashkiv LB,. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med 2012; 209: 319-34.
43. Foucault I, Le Bras S, Charvet C, Moon C, Altman A, Deckert M,. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood 2005; 105: 1106-13.
44. Shukla U, Hatani T, Nakashima K, Ogi K, Sada K,. Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated activation of NFAT. J Biol Chem 2009; 284: 33719-28.
45. Chen G, Dimitriou I, Milne L, Lang KS, Lang PA, Fine N, et al. The 3BP2 adapter protein is required for chemoattractant-mediated neutrophil activation. J Immunol 2012; 189: 2138-50.
46. Ainsua-Enrich E, Alvarez-Errico D, Gilfillan AM, Picado C, Sayos J, Rivera J, et al. The adaptor 3BP2 is required for early and late events in FcεRI signaling in human mast cells. J Immunol 2012; 189: 2727-34.
47. Hendrich C, Kuipers JG, Kolanus W, Hammer M, Schmidt RE,. Activation of CD16+ effector cells by rheumatoid factor complex: role of natural killer cells in rheumatoid arthritis. Arthritis Rheum 1991; 34: 423-31.
48. Cross A, Bucknall RC, Cassatella MA, Edwards SW, Moots RJ,. Synovial fluid neutrophils transcribe and express class II major histocompatibility complex molecules in rheumatoid arthritis. Arthritis Rheum 2003; 48: 2796-806.
49. Malone DG, Wilder RL, Saavedra-Delgado AM, Metcalfe DD,. Mast cell numbers in rheumatoid synovial tissues: correlations with quantitative measures of lymphocytic infiltration and modulation by antiinflammatory therapy. Arthritis Rheum 1987; 30: 130-7.
50. Wang CJ, Chen IP, Koczon-Jaremko B, Boskey AL, Ueki Y, Kuhn L, et al. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties. Bone 2010; 46: 1306-15.